ROS Scavenging and inflammation-directed polydopamine nanoparticles regulate gut immunity and flora therapy in inflammatory bowel disease

• Published in: Acta biomaterialia 2023-04, Vol.161, p.250-264
• Main Authors: Bao, Meiyu, Wang, Keyi, Li, Jingqiang, Li, Yueying, Zhu, Huanhuan, Lu, Meiling, Zhang, Yue, Fan, Qiangyuan, Han, Lin, Wang, Kesheng, Wang, Dongyan, Gao, Yan, Peng, Bo, Ming, Zunzhen, Liu, Weiwei
• Format: Article
• Language: English
• Subjects: Animals; Anti-Inflammatory Agents - therapeutic use; Antimicrobial peptides; Colitis - drug therapy; Cytokines; Dextran Sulfate - therapeutic use; Immunoregulation; Inflammation - drug therapy; Inflammatory Bowel Disease; Inflammatory Bowel Diseases - drug therapy; Inflammatory Bowel Diseases - metabolism; Intestinal microbe; Macrophages - metabolism; Mice; Nanoparticles; Polydopamine nanoparticles; Reactive Oxygen Species - metabolism; RNA, Ribosomal, 16S - genetics
• ISSN: 1742-7061; 1878-7568
• DOI: 10.1016/j.actbio.2023.02.026

Dysfunction of the intestinal mucosal immune system and dysbiosis of the intestinal microflora can induce inflammatory bowel disease. However, drug-mediated clinical treatment remains a challenge due to its poor therapeutic efficacy and severe side effects. Herein, a ROS scavenging and inflammation-directed nanomedicine is designed and fabricated by coupling polydopamine nanoparticles with mCRAMP, an antimicrobial peptide, while wrapping macrophage membrane in the outer layer. The designed nanomedicine reduced the secretion of pro-inflammatory cytokines and elevate the expression of anti-inflammatory cytokine in vivo and in vitro inflammation models, demonstrating its significant ability of improving inflammatory responses. Importantly, the macrophage membrane encapsulated nanoparticles exhibit the obviously enhanced targeting performance in local inflamed tissues. Furthermore, the 16S rRNA sequencing of fecal microorganisms showed that probiotics increased and pathogenic bacteria were inhibited after oral delivery the nanomedicine, indicating that the designed nano platform played a significant role in optimizing intestinal microbiome. Taken together, the designed nanomedicine are not only easy to prepare and exhibit high biocompatibility, but also show the inflammatory targeting property, anti-inflammatory function and positive regulation of intestinal flora, thus providing a new idea for the intervention and treatment of colitis. Inflammatory bowel disease (IBD), a chronic and intractable disease, may lead to colon cancer in severe cases without effective treatment. However, clinical drugs are largely ineffective owing to insufficient therapeutic efficacies and side effects. Herein, we constructed a biomimetic polydopamine nanoparticle for oral administration to treat the IBD by modulating mucosal immune homeostasis and optimizing intestinal microorganisms. In vitro and in vivo experiments showed that the designed nanomedicine not only exhibits the anti-inflammatory function and inflammatory targeting property but also positively regulate the gut microflora. Taken together, the designed nanomedicine combined immunoregulation and intestinal microecology modulation to significantly enhance the therapeutic effect on colitis in mice, thus providing a new approach for the clinical treatment of colitis. [Display omitted]